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Abstract
Background: An inverse relationship between allergies with glioma risk has been reported in several but not all
epidemiological observational studies. We performed an analysis of genetic variants associated with atopy to assess
the relationship with glioma risk using Mendelian randomisation (MR), an approach unaffected by biases from
temporal variability and reverse causation that might have affected earlier investigations.
Methods: Two-sample MR was undertaken using genome-wide association study data. We used single nucleotide
polymorphisms (SNPs) associated with atopic dermatitis, asthma and hay fever, IgE levels, and self-reported allergy
as instrumental variables. We calculated MR estimates for the odds ratio (OR) for each risk factor with glioma using
SNP-glioma estimates from 12,488 cases and 18,169 controls, using inverse-variance weighting (IVW), maximum
likelihood estimation (MLE), weighted median estimate (WME) and mode-based estimate (MBE) methods. Violation
of MR assumptions due to directional pleiotropy were sought using MR-Egger regression and HEIDI-outlier analysis.
Results: Under IVW, MLE, WME and MBE methods, associations between glioma risk with asthma and hay
fever, self-reported allergy and IgE levels were non-significant. An inverse relationship between atopic
dermatitis and glioma risk was found by IVW (OR 0.96, 95% confidence interval (CI) 0.93–1.00, P = 0.041) and
MLE (OR 0.96, 95% CI 0.94–0.99, P = 0.003), but not by WME (OR 0.96, 95% CI 0.91–1.01, P = 0.114) or MBE
(OR 0.97, 95% CI 0.92–1.02, P = 0.194).
Conclusions: Our investigation does not provide strong evidence for relationship between atopy and the risk
of developing glioma, but findings do not preclude a small effect in relation to atopic dermatitis. Our analysis
also serves to illustrate the value of using several MR methods to derive robust conclusions.
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Background
Although glioma accounts for approximately 80% of
malignant primary brain tumours [1], to date, few
aetiological risk factors are well established for the dis-
ease [2]. Over the past three decades the search for an
immune-mediated risk factor that might influence risk
has led to studies of a possible relationship between
multiple allergic conditions and autoimmune disorders
with glioma [3].
Several case-control studies have shown that self-
reported allergic conditions may protect against glioma
[4]. For example, in the International Adult Brain
Tumour Study, based on 1178 glioma patients, an odds
ratio (OR) of 0.59 was found for any self-reported allergy
[5]. Other case-control studies have reported similar
ORs, however, most have been reliant on substantial
numbers of proxy informants (up to 44%) [4, 6] and
have potential bias as a consequence of how controls
were ascertained, thereby casting doubt on findings. In
contrast to case-control studies, evidence for an associ-
ation between glioma and allergy from cohort-based
analyses has been less forthcoming [7], although such
studies have been poorly powered to demonstrate a
relationship.
Assaying IgE potentially reduces bias stemming from
self-reporting despite levels not necessarily correspond-
ing to specific allergies or equating to a single allergic
response. Nevertheless, measurement of IgE has been
explored by a number of researchers seeking to identify
risk factors for glioma [8–10]. In a case-control study of
228 cases and 289 controls performed in 2004 [8], self-
reported allergies and IgE levels were both inversely as-
sociated with glioma, but concordance between the two
outcomes was poor. In a larger study of 535 cases and
532 controls [11], both self-reported allergies and IgE
levels were inversely related to glioma risk; however, IgE
levels in patients were affected by temozolomide treat-
ment. A case-control study nested within the European
Prospective Investigation into Cancer and Nutrition co-
hort based on prospectively collected serum IgE levels
reported a non-significant OR of 0.73 [9]. A similar
nested case-control study performed in the USA based
on 181 cases reported a non-significant OR of 0.72 for
high serum IgE [10].
Several mechanisms have been proposed to explain a
possible association between atopic disease and glioma
[12]. The findings could reflect a true causal effect of the
heightened immune function reported for atopy on
tumour development. Alternatively, the associations ob-
served might be non-causal, arising as a consequence of
methodological biases inherent in the study design. Impre-
cisely defined exposures, such as allergic disease, are likely
to have affected the validity of the findings of both case-
control and cohort studies. The heterogeneous description
of allergy in studies and different levels of detail in self-
reporting on individual allergies complicate the inter-
pretation of results. Additional biases include possible
selection bias in controls, recall bias from self-reported
allergy assessment and reverse causation or confound-
ing from unmeasured effects. Finally, the high fre-
quency of exposure ascertainment by proxy for cases is
also likely to have systematically biased findings.
Mendelian randomisation (MR) analysis can be used
to minimise potential biases in conventional observa-
tional studies and to determine the causal association of
an exposure with an outcome such as disease risk [13].
The causal association can also be manifested by com-
mon genetic and biological pathways that determine two
sequentially developed phenotypes such as an atopic
trait and glioma risk. Atopy has a strong heritable basis
[14, 15] and, thus far, genome-wide association studies
(GWAS) have identified over 50 loci associated with
different atopy-related traits [16]. The alleles associated
with atopy should be randomly assigned to offspring
from parents during mitosis, a process analogous to the
random assignment of subjects to an exposure of inter-
est in randomised clinical trials. Thus, genetic scores
summarising the effects of single nucleotide polymor-
phisms (SNPs) associated with atopy-related traits can
serve as instrumental variables (IVs) in a MR analysis of
atopy and glioma risk.
To examine the nature of the association between atopy
and glioma, we implemented two-sample MR [17] to
estimate associations between atopy-associated SNPs and
glioma risk using summary data from the recent GWAS
meta-analysis performed by the Glioma International
Case-Control Consortium study [18].
Methods
Two-sample MR was undertaken using GWAS data.
Ethical approval was not sought for this specific project
because all data came from the summary statistics of pub-
lished GWAS, and no individual-level data were used.
Glioma genotyping data
Glioma genotyping data were derived from the most recent
meta-analysis of GWAS in glioma, which related > 10 mil-
lion genetic variants (after imputation) to glioma, in 12,488
glioma patients and 18,169 controls from eight independent
GWAS datasets of individuals of European descent [18]
(Additional file 1: Table S1). Comprehensive details of the
genotyping and quality control of the seven GWAS have
been previously reported [18].
Genetic variant instruments for atopic traits
SNPs associated with each of the atopy-related traits
investigated, namely atopic dermatitis (eczema), asthma
and hay fever, IgE level, and self-reported allergy, by the
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NHGRI-EBI GWAS Catalog [19–26] at genome-wide
significance (i.e. P ≤ 5.0 × 10− 8) in individuals with
European ancestry were used as IVs. To avoid co-linearity
between SNPs for each trait, we excluded SNPs that were
correlated (i.e. r2 value of ≥ 0.001) within each trait, and
only considered the SNPs with the strongest effect on the
trait for use as IVs (Additional file 2: Table S2). For each
SNP, we recovered the chromosome position, risk allele,
association estimates (per-allele log-OR) and standard
errors (Table 1). The allele that was associated with
increased risk of the exposure was considered the effect
allele. For IgE level, the allele associated with an increase
in serum IgE was considered the effect allele. Allele fre-
quencies for these SNPs were compared between the
atopy-related trait and glioma datasets to ensure that the
effect estimates were recorded with respect to the same
allele. Gliomas are heterogeneous and different tumour
subtypes, defined in part by malignancy grade (e.g. pilo-
cytic astrocytoma World Health Organization (WHO)
grade I, diffuse ‘low-grade’ glioma WHO grade II, ana-
plastic glioma WHO grade III and glioblastoma (GBM)
WHO grade IV) can be distinguished [27]. For the sake
of brevity we considered gliomas as being either GBM
or non-GBM.
Two-sample MR method
The association between each atopy-related trait and gli-
oma was examined using MR on summary statistics
using the inverse-variance weighting (IVW) method and
maximum likelihood estimation (MLE) as per Burgess et
al. [28]. The IVW ratio estimate ðβ^Þ of all SNPs associ-
ated with each atopy-related trait on glioma risk was cal-
culated as follows:
β^ ¼
P
kXkY kσY
−2
kP
kX
2
kσY
−2
k
Where Xk corresponds to the association of SNP k (as
log of the OR per risk allele) with the atopy-related trait
Yk is the association between SNP k and glioma risk (as
log OR) with standard error σY k . The estimate for ðβ^Þ
represents the causal increase in the log odds of gli-
oma for each trait. The standard error of the com-
bined ratio estimate is given by:
se β^
 
¼
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For the MLE, a bivariate normal distribution for the
genetic associations was assumed, and the R function
optim was used to estimate β. seðβ^Þ was calculated using
observed information. The correlation between the er-
rors of Yk and Xk was taken to be 0 as they were derived
from independent studies.
A central tenet in MR is the absence of pleiotropy (i.e.
a gene influencing multiple traits) between the SNPs
influencing the exposure and outcome disease risk [13].
This would be revealed as deviation from a linear rela-
tionship between SNPs and their effect size for atopy
and glioma risk. To examine for violation of the stand-
ard IV assumptions in our analysis we first performed
MR-Egger regression, as well as HEIDI-outlier analysis,
as per Zhu et al. [29], imposing the advocated threshold
of P ≤ 0.01. Additionally, we derived weighted median
estimates (WME) [30] and mode-based estimates (MBE)
[31] to establish the robustness of findings.
Atopic dermatitis, asthma and hay fever, and self-
reported allergy as well as all of the disease outcomes (all
glioma, GBM and non-GBM glioma) are binary. The
causal effect estimates therefore represent the odds for
outcome disease risk per unit increase in the log OR of
the exposure disease [32]. These ORs were converted to
represent the OR for the outcome disease per doubling in
odds of the exposure disease to aid interpretation [32].
For each statistical test we considered a global signifi-
cance level of P < 0.05 as being satisfactory to derive con-
clusions. To assess the robustness of our conclusions, we
initially imposed a conservative Bonferroni-corrected sig-
nificance threshold of 0.0125 (i.e. 0.05/4 atopy-related
traits). We considered a P value ≥ 0.05 as non-significant
(i.e. no association), a P < 0.05 as evidence for a potential
causal association, and a P < 0.0125 as significant evidence
for an association. All statistical analyses were undertaken
using R software (Version 3.1.2). The meta and gsmr
packages were used to generate forest plots and perform
HEIDI-outlier analysis [29].
The power of a MR investigation depends greatly on
the proportion of variance in the risk factor that is ex-
plained by the IV. We estimated study power a priori
using the methodology of Burgess et al. [33], making use
of published estimates of the heritability of trait associ-
ated IV SNPs [34–36], as well as estimates found by
direct calculation (Additional file 3: Table S3), and the
reported effect of each trait on glioma risk reported in a
meta-analysis of epidemiological studies [18]. Additional
file 4: Table S4 shows the range of ORs for which we
had less than 80% power to detect for each of the four
atopy-related traits.
Simulation model
Through simulation we evaluated the suitability of using
each employed MR method in a two-sample setting with
binary-exposure and binary-outcome data. Let i index
genetic variants, N be the total number of genetic variants,
and j index individuals. Genetic variants gij were generated
independently by sampling from a Binomial(2,pj) distribu-
tion with probability pj drawn from a Uniform(0.1,0.9) dis-
tribution, to mimic bi-allelic SNPs in Hardy–Weinberg
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Table 1 Variant and effect allele with frequencies and magnitude of effect on each atopy-related trait and strength of association
with glioma
Region SNP Position (bp)a Allelesb MAF Hay fever and asthma Glioma
OR (95% CI) OR (95% CI)
2q12.1 rs10197862 102,966,549 G/A G = 0.161 1.24 (1.16–1.32) 0.98 (0.93−1.03)
4p14 rs4833095 38,799,710 C/T T = 0.425 1.20 (1.14–1.26) 1.03 (0.99−1.08)
5q22.1 rs1837253 110,401,872 T/C T = 0.382 1.17 (1.11–1.23) 0.96 (0.93−1.00)
8q21.13 rs7009110 81,291,879 C/T C = 0.467 1.14 (1.09–1.19) 0.98 (0.94−1.01)
9p24.1 rs72699186 6,175,855 A/T T = 0.110 1.26 (1.17–1.36) 0.97 (0.93−1.02)
11q13.5 rs2155219 76,299,194 G/T G = 0.468 1.17 (1.13–1.21) 1.01 (0.97−1.05)
15q22.33 rs17294280 67,468,285 A/G G = 0.120 1.18 (1.12–1.25) 0.98 (0.94−1.03)
16p13.13 rs62026376 11,228,712 T/C T = 0.144 1.17 (1.11–1.23) 0.97 (0.93−1.01)
17q21.1 rs7212938 38,122,680 T/G G = 0.473 1.16 (1.11–1.22) 1.00 (0.97−1.04)
Region SNP Positiona Allelesb MAF Atopic dermatitis Glioma
OR (95% CI) OR (95% CI)
1q21.3 rs11205006 152,440,176 T/A A = 0.265 1.62 (1.48–1.77) 0.96 (0.91−1.02)
1q21.3 rs2228145 154,426,970 A/C C = 0.293 1.15 (1.10–1.20) 0.99 (0.96−1.03)
2p25.1 rs10199605 8,495,097 A/G A = 0.244 1.04 (1.03–1.06) 1.01 (0.97−1.05)
2p13.3 rs112111458 71,100,105 G/A G = 0.224 1.08 (1.05–1.10) 0.98 (0.92−1.03)
2q24.3 rs6720763 167,992,286 T/C C = 0.320 1.29 (1.18–1.41) 1.02 (0.97−1.06)
5p13.2 rs10214237 35,883,734 C/T C = 0.176 1.06 (1.05–1.08) 0.98 (0.94−1.02)
5q31.1 rs1295686 131,995,843 C/T T = 0.422 1.35 (1.22–1.49) 0.99 (0.95−1.03)
6p21.32 rs12153855 32,074,804 T/C C = 0.125 1.58 (1.40–1.78) 0.97 (0.92−1.03)
8q21.13 rs6473227 81,285,892 A/C A = 0.473 1.06 (1.05–1.08) 0.98 (0.94−1.02)
9p21.3 rs10738626 22,373,457 C/T C = 0.397 1.23 (1.15–1.32) 0.96 (0.93−1.00)
10p15.1 rs6602364 6,038,853 G/C G = 0.492 1.05 (1.03–1.07) 1.03 (0.99−1.07)
11q13.1 rs10791824 65,559,266 A/G G = 0.490 1.15 (1.12–1.19) 0.99 (0.95−1.02)
11q24.3 rs7127307 128,187,383 C/T C = 0.488 1.09 (1.07–1.11) 0.99 (0.95−1.03)
11q13.5 rs7130588 76,270,683 G/A G = 0.216 1.29 (1.20–1.38) 1.02 (0.98−1.06)
14q13.2 rs2143950 35,572,357 C/T T = 0.215 1.08 (1.06–1.10) 1.01 (0.97−1.06)
16p13.13 rs2041733 11,229,589 C/T T = 0.496 1.09 (1.06–1.11) 0.97 (0.94−1.01)
19p13.2 rs2164983 8,789,381 C/A A = 0.169 1.16 (1.10–1.22) 0.95 (0.90−1.00)
20q13.33 rs909341 62,328,742 T/C T = 0.262 1.32 (1.21–1.44) 1.32 (1.26−1.37)
Region SNP Positiona Allelesb MAF IgE levelc Glioma
OR (95% CI) OR (95% CI)
1q23.2 rs2251746 159,272,060 C/T C = 0.015 1.09 (1.08–1.11) 0.98 (0.95−1.02)
5q31.1 rs20541 131,995,964 A/G A = 0.270 1.08 (1.06–1.10) 1.01 (0.97−1.06)
6p22.1 rs2571391 29,923,838 C/A C = 0.303 1.06 (1.05–1.08) 0.97 (0.94−1.01)
6p21.32 rs2858331 32,681,277 A/G G = 0.490 1.04 (1.03–1.06) 1.02 (0.98−1.06)
12q13.3 rs1059513 57,489,709 C/T C = 0.070 1.13 (1.09–1.17) 0.97 (0.92−1.03)
Region SNP Positiona Allelesb MAF Self–reported allergy Glioma
OR (95% CI) OR (95% CI)
2q12.1 rs10189699 102,879,464 A/C A = 0.143 1.16 (1.12–1.20) 0.99 (0.94−1.04)
2q33.1 rs10497813 198,914,072 T/G T = 0.401 1.08 (1.05–1.11) 0.99 (0.96−1.03)
3q28 rs9860547 188,128,979 G/A A = 0.272 1.08 (1.05–1.11) 1.02 (0.98−1.06)
4p14 rs2101521 38,811,551 A/G A = 0.475 1.15 (1.12–1.18) 1.02 (0.98−1.07)
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equilibrium. Let wj correspond to the per-allele OR for the
exposure disease, sampled from ORs reported for
genome-wide significant SNPs reported in the GWAS
Catalog [37], and v be the OR for the outcome disease per
doubling in odds of the exposure disease. For each indi-
vidual, exposure disease odds xj, outcome disease odds yj,
exposure disease status aj, and outcome disease status bj
were determined as follows:
x j ¼ x0
YN
i¼1
wi
gij
y j ¼ y0  2 log2x j log2v
a j  Binomial 1; x j1þ x j
 
bj  Binomial 1;
y j
1þ y j
 !
Data for 1,000,000 individuals were simulated and parti-
tioned at random to reflect the two-sample setting. Cases
and controls for the exposure and outcome GWAS were
sampled from each half of the dataset using the exposure
and outcome disease statuses of each individual, and asso-
ciation statistics computed under an additive logistic re-
gression model. To ensure the simulated data closely
resembled the atopy-related trait and glioma data, the
simulation analysis was repeated for each binary atopy-
related trait using the same number of genetic variants as
IVs and the same numbers of case and control individuals
as used to estimate the atopy-related trait and glioma asso-
ciation statistics (Additional file 5: Table S5). Parameters x0
= 0.0005 and y0 = 0.01 were chosen to ensure the preva-
lence of the simulated exposure and outcome diseases were
similar to that of the atopy-related traits and glioma,
respectively (Additional file 5: Table S5). To determine the
suitability of each MR method we considered two scenar-
ios: (1) no causal relationship between exposure and out-
come (v = 1.00) and (2) a causal relationship between
exposure and outcome (v = 1.33). We performed 100 simu-
lations for each scenario for each binary atopy-related trait.
Results
The atopic dermatitis risk SNP rs909341, which is highly
correlated with the chromosome 20q13.33 glioma risk
SNP rs2297440 (D’ = 0.89, r2 = 0.77), was strongly asso-
ciated with risk of glioma (P = 2.10 × 10−34). Testing for
pleiotropy using HEIDI-outlier analysis formally identi-
fied rs909341 as violating the assumption of the instru-
ment on the outcome. Henceforth, we confined our
analysis of the relationship between atopic dermatitis
and glioma to a dataset excluding this SNP.
Figure 1 shows forest plots of ORs for glioma gener-
ated from the SNPs. There was minimal evidence of
heterogeneity between variants for asthma and hay fever,
atopic dermatitis, IgE levels and self-reported allergy (re-
spective I2 and Phet values being 28% and 0.192, 8% and
0.377, 0% and 0.444, and 0% and 0.707). Including
rs909341 in the analysis for atopic dermatitis, the I2 value
was 90% and Phet < 10
− 4 (Additional file 6: Figure S1),
providing further evidence that inclusion of this SNP
would invalidate the MR analysis.
The results of the IVW, MLE, WME, MBE and MR-
Egger methods are summarised in Table 2. Using the
IVW method to pool results from individual SNPs, no
associations (i.e. P ≥ 0.05) were identified between gen-
etically conferred risk of raised IgE level (OR 0.88, 95%
CI 0.69–1.13, P = 0.319), asthma and hay fever (OR 0.96,
95% CI 0.90–1.03, P = 0.248), or self-reported allergy
(OR 1.03, 95% CI 0.95–1.11, P = 0.534) with risk of all gli-
oma. There was some support for an inverse relationship
Table 1 Variant and effect allele with frequencies and magnitude of effect on each atopy-related trait and strength of association
with glioma (Continued)
4q27 rs17388568 123,329,369 G/A A = 0.141 1.08 (1.05–1.11) 1.01 (0.97−1.05)
5p13.1 rs7720838 40,486,896 G/T T = 0.362 1.08 (1.06–1.11) 1.02 (0.99−1.06)
5q22.1 rs1438673 110,467,499 T/C C = 0.296 1.12 (1.09–1.15) 0.97 (0.94−1.01)
6p21.33 rs9266772 31,352,113 T/C C = 0.175 1.11 (1.08–1.14) 1.03 (0.98−1.08)
9p24.1 rs7032572 6,172,380 A/G G = 0.114 1.12 (1.08–1.16) 0.97 (0.93−1.02)
10p14 rs962993 9,053,132 T/C T = 0.106 1.07 (1.05–1.10) 1.02 (0.98−1.06)
11q13.5 rs2155219 76,999,194 G/T G = 0.468 1.11 (1.09–1.14) 1.01 (0.97−1.05)
15q22.33 rs17228058 67,450,305 A/G G = 0.100 1.08 (1.05–1.11) 1.00 (0.96−1.04)
17q21.1 rs9303280 38,074,031 T/C T = 0.346 1.07 (1.05–1.09) 0.98 (0.94−1.02)
20q13.2 rs6021270 50,141,264 C/T T = 0.346 1.16 (1.10–1.22) 1.02 (0.94−1.10)
aNCBI build 37
bReference allele/effect allele
cPer standard deviation
MAF minor allele frequency, OR odds ratio, SNP single nucleotide polymorphism
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between atopic dermatitis and glioma risk (OR 0.96, 95%
CI 0.93–1.00, P = 0.041), albeit not significant after adjust-
ment for multiple testing.
Using MLE, no associations were identified between
asthma and hay fever (OR 0.96, 95% CI 0.93–1.00,
P = 0.066), IgE levels (OR 0.88, 95% CI 0.74–1.05,
P = 0.157) or self-reported allergy (OR 1.02, 95% CI
0.97–1.08, P = 0.429) with risk of all glioma. For
atopic dermatitis, an OR of 0.96 (95% CI 0.94–0.99,
P = 0.003) was shown, which remained significant
after adjusting for multiple testing. Figure 2 shows
relaxation of the assumption that the correlation
between the errors in Xk and Yk is zero for each of
the atopy-related traits demonstrating the consistency of
findings. Specifically, for a correlation in the range −0.15
to 0.15, the association between atopic dermatitis and
glioma risk remained significant.
In contrast to findings from IVW and MLE, no signifi-
cant support was provided by either the WME or MBE
for an association between any of the atopy-related traits
and glioma risk, including atopic dermatitis (WME: OR
0.96, 95% CI 0.91–1.01, P = 0.114; MBE: OR 0.97, 95%
CI 0.92–1.02, P = 0.194; Table 2).
The respective effect estimated from MR-Egger regres-
sion (Fig. 3) were 0.97 for atopic dermatitis (95% CI
0.92–1.03; P = 0.375), 0.63 for IgE levels (95% CI 0.32–
1.25; P = 0.184), 0.99 for asthma and hay fever (95% CI
0.72–1.36, P = 0.951) and 0.92 for self-reported allergy
(95% CI 0.69–1.22; P = 0.540), with intercepts of −0.004
(95% CI −0.014 to 0.006, P = 0.396), 0.027 (95% CI 0.001
to 0.053, P = 0.042), −0.007 (95% CI −0.030 to 0.016, P =
0.542) and 0.017 (95% CI 0.003–0.031, P = 0.018). Collect-
ively, these findings provide possible evidence of systematic
bias in the IVW estimate for IgE level and self-reported
allergy, which might have arisen through overall unbal-
anced horizontal pleiotropy. There was no such evidence
for such pleiotropy in respect of atopic dermatitis.
We explored the possibility that a relationship between
atopy and glioma might be subtype specific, considering
GBM and non-GBM separately. Imposing a stronger
significance threshold of P = 0.00625 (0.05/8, to correct
for testing four traits over two outcomes), no histology-
specific associations were shown by the IVW method
between asthma and hay fever, IgE levels and self-
reported allergy and glioma risk, with the respective
ORs for the IVW method being 0.97, 0.92 and 1.04 for
a b
c d
Fig. 1 Forest plot of Wald odds ratios (ORs) and 95% confidence intervals generated from single nucleotide polymorphisms (SNPs) associated
with atopy-related traits. ORs for individual SNPs are listed according to magnitude of effect in the instrumental variable analysis and are
presented with pooled effects using the inverse-variance weighting method. Squares represent the point estimate, and the bars are the 95%
confidence intervals. a Asthma and hay fever, b atopic dermatitis, c IgE level, d self-reported allergy
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GBM tumours, and 0.96, 0.97 and 1.04 for non-GBM
tumours (Additional file 7: Table S6). For atopic derma-
titis, a significant OR of 0.94 (95% CI 0.90–0.98, P =
0.004) was shown for GBM but not for non-GBM (OR
0.98, 95% CI 0.93–1.03, P = 0.421). The association be-
tween atopic dermatitis and risk of GBM was also appar-
ent in the MLE analysis, which provided an OR of 0.94
(95% CI 0.91–0.97, P = 2.17 × 10− 4). MR-Egger regres-
sion provided for an intercept of −0.007 (95% CI −0.019
to 0.005, P = 0.247). As with the analysis of all glioma,
the association between atopic dermatitis and GBM
was weaker under the WME (OR 0.96, 95% CI 0.91–
1.02, P = 0.172) and MBE (OR 0.95, 95% CI 0.90–1.01,
P = 0.096) frameworks.
Although previously implemented in other studies
[32, 38], ratio estimators may not fully recapitulate an
estimate of the causal OR in the case of binary expo-
sures, such as atopic dermatitis, and binary outcomes
such as glioma [39]. We therefore evaluated, through
simulation, whether the IVW, MLE, WME, MBE and MR-
Egger methods provide reliable estimates of causal ORs.
When no causal relationship between exposure and out-
come was simulated, each MR method provided accurate
estimates of the null relationship (Additional file 5: Table
S5). Conversely, when a causal relationship was simulated,
the magnitudes of the relationship estimates were weakly
inflated in some instances (Additional file 5: Table S5), indi-
cating the importance of considering additional evidence
when evaluating causal relationships between binary expo-
sures and binary outcomes.
Discussion
To our knowledge, this is the first MR study evaluating
a range of atopy-related traits with glioma risk. Overall,
our results provide evidence for a causal protective effect
of atopic dermatitis with GBM tumours, but do not pro-
vide evidence that asthma and hay fever, raised IgE
Fig. 2 Plot of P value of maximum likelihood estimation associations with glioma against correlation between errors in Xk and Yk. a Asthma and
hay fever, b atopic dermatitis, c IgE level, d self-reported allergy
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levels, or self-reported allergy is protective against the
risk of developing glioma.
Possible mechanisms explaining an observed inverse
relation between the risk of atopic dermatitis and the
risk of glioma have been suggested in previous papers
[12], postulated to be the consequence of immune sys-
tem hyperactivity. The question thus arises as to how
such divergent findings for other atopic traits can be ex-
plained or reconciled, when they have been previously
reported in high numbers.
A key assumption in MR is that the instrument affects
glioma risk through its effect on a specific phenotype/
exposure (i.e. atopic traits), and does not have a direct
effect on glioma risk. We tested this assumption using
MR-Egger regression and HEIDI-outlier analysis and
found possible evidence of violation of this assumption
for IgE and self-reported allergy. It is notable that self-
reported allergy does not show an approximately quad-
ratic response to correlation, in contrast to asthma and
hay fever, atopic dermatitis and IgE level. This is likely
to be a consequence of imprecise estimates of the associ-
ation between SNPs and allergy, illustrating the inherent
issue in attempting to make use of self-reported allergy
data as an atopy-related trait.
The meta-analyses of published epidemiological obser-
vational studies has indeed provided strong evidence for
an inverse relationship between atopy and glioma risk
[40]. However, most of the support for such a relation-
ship came from case-control studies [4]. A common
limitation in retrospective studies of glioma has been the
use of proxy respondents for patients with cognitive
impairment, who may not remember past exposures ac-
curately due to cognitive deficits [4]. Such issues are
compounded by the fact that, across studies, multiple
atopic traits have been assessed. The strength of support
for a relationship seen across case-control studies con-
trasts markedly with the limited evidence for a relation-
ship from prospective cohort-based analyses [7].
Fig. 3 Scatter plots of genetic associations with glioma against genetic associations with the exposure. a Asthma and hay fever, b atopic
dermatitis, c IgE level, d self-reported allergy
Disney-Hogg et al. BMC Medicine  (2018) 16:42 Page 9 of 13
By inference, a relationship between long-term antihista-
mine use could theoretically provide supporting evidence,
albeit indirect, that atopic-mediated mechanisms influence
glioma risk. However, the impact of antihistamine use is dif-
ficult to disentangle from that of allergies, as these factors
are highly correlated and few individuals without allergies
use antihistamines regularly. Paradoxically, an increased
risk for glioma associated with antihistamines, particularly
among individuals with allergic conditions, has been found
in some studies [41, 42].
Raised IgE levels and self-reported allergy suffer limita-
tions as traits used to assess the effect of atopy on gli-
oma risk as they are both variable over short time scales
in their level of expression (in contrast to clinical diag-
nosis of atopic dermatitis). Further, allergies may develop
later in life, and patients may not necessarily exhibit
symptoms. This introduces the possibility of bias and
error due to the time varying association of SNPs with
the exposure. However, it has been suggested that sea-
sonality does not have a significant effect [11].
An additional possible explanation for the lack of
causal association between IgE levels and glioma risk
seen in this study is that the causality is in fact reversed,
which could result in epidemiological observational
studies reporting inverse relationships [8, 9], but would
not affect an MR analysis. Immunosuppression caused
by glioblastoma is well documented [43, 44] and may
lead to reduced expression of atopy. Furthermore, in
addition to steroids, temozolomide therapy, routinely
used to treat GBM nowadays, leads to reduced blood
IgE levels [11].
Using data from large genetic consortia for multiple
atopy-related traits and glioma risk has enabled us to
more precisely test our study hypotheses than if we had
used individual-level data from a smaller study. Through
simulation scenarios, the IVW, MLE, WME, MBE and
MR-Egger methods have been demonstrated to accur-
ately estimate causal effects using summary-level data
[28, 30, 31, 45]. However, using summary-level data in-
stead of individual-level data limits the approaches that
can be used to test the validity of genetic variants as IVs,
as adjusting for measured covariates and assessing gene-
environment interactions is generally not possible using
summary-level data [46]. The first-stage F statistic was
large (> 25 for all traits), and therefore weak instrument
bias is unlikely.
Epidemiological observational studies have reported
inverse relationships between atopy-related traits and
glioma risk, with ORs in the range 0.43–0.96 for asthma
[6, 47], 0.42–0.90 for atopic dermatitis [6, 47], 0.37–0.73
for IgE levels [8–10] and 0.47–0.69 for self-reported
allergies [4, 5, 8]. Odds ratios for binary exposures
estimated in this MR study represent the OR for the
outcome disease per doubling in odds of the exposure
disease, and the magnitudes of these causal effect esti-
mates are therefore not directly comparable to those
reported in observational studies.
Our MR analysis has several strengths. Firstly, by utilis-
ing the random allocation of genetic variants, we were
able to overcome potential confounding and reverse caus-
ation that may bias estimates from observational studies.
Secondly, given that a poor outcome from glioma is al-
most universal, it is unlikely that survival bias will have in-
fluenced study findings. Lastly, the findings from this
study represent the association of a lifelong atopy with
glioma in the general European population.
Nevertheless, our study does have limitations. Firstly,
while it is entirely appropriate to implement different
MR methods to assess the robustness of findings, they
have a differing power to demonstrate associations, with
the WME, MBE and MR-Egger methods having less
power than IVW and MLE. Irrespective of such factors,
our study only had 80% power to detect ORs of 1.16,
1.09, 1.16 and 1.22 for asthma and hay fever, atopic
dermatitis, IgE level and self-reported allergy, respect-
ively (Additional file 4: Table S4), due to the very low
proportion of variability in the atopy-related traits ex-
plained by the SNPs used. Hence, we cannot exclude the
possibility that these traits influence glioma risk, albeit
modestly. To explore this possibility, will require add-
itional IVs and larger sample sizes affording increased
power. Furthermore, it is possible that an effect of atopy
on glioma risk might be mediated through mechanisms
associated with a trait that we have not captured by
using MR to assess asthma and hay fever and self-
reported allergy. Secondly, a weakness of the two-sample
MR strategy is that it does not allow examination of
non-linear relationships between exposures and out-
comes. Finally, we have sought to examine whether bias
could be introduced when considering a binary exposure
for a binary outcome. Although in our simulation study
we found no evidence of bias when estimating non-
causal relationships, we did not extend our analysis to
consider the potential impact of invalid SNPs.
Conclusions
In conclusion, our investigation does not provide strong
evidence for a relationship between atopy-related dis-
eases and risk of developing glioma, but findings do not
preclude a small effect for atopic dermatitis. Our ana-
lysis also serves to illustrate the value of using several
MR methods to derive robust conclusions.
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